MentionFox
Home › Executive changes › Definium Therapeutics, Inc.
Leadership changes · DFTX · SEC Form 8-K, Item 5.02

Leadership changes at Definium Therapeutics, Inc. (2026)

Before you join, sell to or invest in Definium Therapeutics, Inc.

MentionFox check on Definium Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/definium-therapeutics

Check Definium Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Definium Therapeutics, Inc.?

Who joined and who left Definium Therapeutics, Inc. (DFTX)? 1 filing reported on 2026-01-29, each cited to the company's own filing.

As of November 14, 2026, Definium Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 29, 2026 (Form 8-K, January 29, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies ↓

Sell to companies like Definium Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-29

Definium Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-29. Every row below is cited to the filing it comes from, and this page adds each new change as Definium Therapeutics, Inc. files it.

Also on the record for Definium Therapeutics, Inc.

DateRecordFigureOur pageSource
November 13, 2026Stake report, Schedule 13G, by Capital World Investors6.1% of the class5%+ stakesSource
November 5, 2026Stake report, Schedule 13G, by FMR LLC6.5% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Commodore Capital LP1.8% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by DRIEHAUS CAPITAL MANAGEMENT LLC5.36% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP3.01% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by Avoro Capital Advisors LLC5.08% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by DRIEHAUS CAPITAL MANAGEMENT LLC6.64% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Commodore Capital LP7.2% of the class5%+ stakesSource
February 13, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP5.54% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Deep Track Capital, LP6.87% of the class5%+ stakesSource
May 5, 2025Form D, private offering$7M soldForm D pageSource

Selling to them or working with them? See who runs Definium Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Definium Therapeutics, Inc. and the records around it.

Definium Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Definium Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Definium Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Definium Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-29Reportednot named in the filing8-K, 2026-01-29
Selling to Definium Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Definium Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Definium Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Definium Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Definium Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-01-29 · 8-K

Reported

Mr. Adsett was not named to any committees in connection with his appointment.

Also stated in this filing

  • On January 28, 2026, the Board of Directors (the "Board") of Definium Therapeutics, Inc. (the "Company"), upon recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from six (6) to seven (7) directors and appointed Roger Adsett to fill the vacancy on the Board, effective January 29, 2026, with a term expiring at the Company's annual general meeting of shareholders to be held in 2026, or until his s uccessor is duly elected or appointed, or until his earlier death, resignation or removal.
  • Mr. Adsett will be compensated in accordance with the Company's non-employee director compensation policy, as amended (the "Policy").
  • Pursuant to the Policy, Mr. Adsett will be entitled to receive $40,000 per year for service as a member of the Board, paid quarterly in arrears on a pro-rata basis.
  • In addition, pursuant to the Policy and in connection with his appointment to the Board as a non-employee director, Mr. Adsett was granted an option to purchase 50,000 common shares of the Company (the "Initial Option Grant"), which will vest one-third on the first anniversary of the grant date, with the remaining portion vesting in equal monthly installments thereafter, subject to Mr. Adsett's continued service on the Board through each applicable vesting date.

Tools for this story

Each opens in a new tab, filled in for Definium Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/definium-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Definium Therapeutics, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/definium-therapeutics